Anterogencoltd Stock Return On Equity
| 065660 Stock | KRW 16,300 650.00 3.83% |
AnterogenCoLtd fundamentals help investors to digest information that contributes to AnterogenCoLtd's financial success or failures. It also enables traders to predict the movement of AnterogenCoLtd Stock. The fundamental analysis module provides a way to measure AnterogenCoLtd's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AnterogenCoLtd stock.
AnterogenCoLtd |
AnterogenCoLtd Company Return On Equity Analysis
AnterogenCoLtd's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current AnterogenCoLtd Return On Equity | -5.92 |
Most of AnterogenCoLtd's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AnterogenCoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, AnterogenCoLtd has a Return On Equity of -5.9178. This is 75.31% lower than that of the Healthcare sector and significantly lower than that of the Pharmaceuticals industry. The return on equity for all Republic of Korea stocks is notably higher than that of the company.
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
AnterogenCoLtd Fundamentals
| Return On Equity | -5.92 | |||
| Return On Asset | -0.0231 | |||
| Profit Margin | (1.32) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 836.51 B | |||
| Shares Outstanding | 7.95 M | |||
| Shares Owned By Insiders | 21.02 % | |||
| Shares Owned By Institutions | 5.63 % | |||
| Price To Sales | 103.53 X | |||
| Revenue | 8.12 B | |||
| Gross Profit | 1.72 B | |||
| EBITDA | (2.96 B) | |||
| Net Income | (553.98 M) | |||
| Cash And Equivalents | 6.97 B | |||
| Debt To Equity | 43.70 % | |||
| Current Ratio | 3.83 X | |||
| Cash Flow From Operations | (3.05 B) | |||
| Beta | 0.37 | |||
| Market Capitalization | 108.41 B | |||
| Total Asset | 136.7 B | |||
| Net Asset | 136.7 B |
About AnterogenCoLtd Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AnterogenCoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnterogenCoLtd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnterogenCoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in AnterogenCoLtd Stock
AnterogenCoLtd financial ratios help investors to determine whether AnterogenCoLtd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AnterogenCoLtd with respect to the benefits of owning AnterogenCoLtd security.